Search
Displaying 411–420 of 556 for “Retinitis pigmentosa”
-
The Foundation Fighting Blindness is inviting you to share your vision-loss journey through written word, audio or video as a part of our October “Share Your Vision” campaign. Help your friends, family, and even people you don’t know, see the world through your eyes—because your story is powerful and unique. #ShareYourVision
-
Full Transcript - 2019 Investing in Cures Summit - March 2, 2019
Full Session Transcripts of the 2019 Investing in Cures Summit.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2022 (July 1, 2021–June 30, 2022)
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
The VISIONS Team is working hard to secure some of the world’s best researchers and clinicians in the field of retinal diseases to speak at VISIONS2018.
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Foundation NewsNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
RD Fund Participates in a €75 Million Series B for SparingVision
In the PressProceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Foundation Fighting Blindness to Host VISIONS 2024 Conference
Foundation NewsThe global conference, held on June 21–22, is dedicated to fostering connection, learning, and empowerment for individuals and families impacted by blinding diseases.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
In the PressThe investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.
